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Report
Regulation of the Cyclin-Dependent Kinase Inhibitor p57Kip2 Expression
by p63
ABSTRACT
The cyclin-dependent kinase (CDK) inhibitor p57Kip2 is a negative regulator of cell
proliferation, binding to a variety of cyclin-CDK complexes and inhibiting their kinase
activities. The p57Kip2 gene was recognized as a target gene for p73β, one member of
the p53 family. In spite of this, the phenotypes of p73 and p57Kip2 knockout mice do not
resemble each other while there is a phenotypic overlap betweeen the p57Kip2 null mice,
the p63 null mice and patients affected by p63 associated syndromes, suggesting that
p57kip2 could be indeed a downstream target of p63. By ChIP we determined that in the
HaCaT cell line the ∆Np63α protein is associated to three different regions of the p57Kip2
gene. ∆Np63 can activate both the endogenous p57Kip2 gene and a reporter vector
containing a -2191 promoter fragment of the p57Kip2 gene. Natural p63 mutants, asso-
ciated to the AEC syndrome, show a partial or complete lack of transactivation potential
of the p57kip2 promoter, while three other natural p63 mutants, associated to the EEC,
LMS and SHFM-4 syndromes, were less affected. These data suggests that p63 play an
important role in the regulation of p57Kip2 expression and that this regulation is subverted
in AEC p63 mutants.
INTRODUCTION
Progression of the cell cycle is promoted by cyclin dependent kinases (CDKs). The
activity of cyclin-CDK complexes is regulated by various mechanisms, including association
of the kinase subunit with the regulatory cyclin subunit, phosphorylation-dephosphorylation
of the kinase subunit, and association of the complex with CDK inhibitors (CKIs).1,2 To
date, seven CKIs have been identified in mammals, and these proteins are classified into
two families on the basis of their amino acid sequence similarity and putative targets.3,4
The Cip or Kip family comprises p21Cip1, p27Kip1 and p57Kip2, each of which possesses a
conserved domain, termed the CDK binding-inhibitory domain, at its NH2 terminus.
The Ink4 family consists of p16Ink4A, p15Ink4B, p18Ink4C and p19Ink4D, and its members
each contains four tandem repeats of an ankyrin motif. Whereas members of the Ink4
family inhibit the activity of CDK4 or CDK6 specifically, members of the Cip-Kip family
inhibit a broad spectrum of cyclin-CDK complexes.
p57Kip2 is ubiquitousoly expressed in the whole embryo and its signal decreases during
development.5,6 The human p57Kip2 gene is located on chromosome 11p15.5, a site of
frequent loss of heterozygosity in several human cancers.7,8 Furthermore, rearrangements
at 11p15 are apparent in individuals with Beckwith-Wiedemann syndrome, which is
characterized by numerous developmental abnormalities as well as a 1,000-fold increase in
the risk of childhood tumors.9-11 Mice lacking p57Kip2 die immediately after birth as a
result of dyspnea caused by severe cleft palate. They also show abdominal muscle defects
and skeletal abnormalities due to defects in endochondral ossification.12-14 The p57Kip2
gene was recently isolated as a target of the p73β transcription factor, one member of the
p53 family.15 It is interesting to note however that p73 null mice show several develop-
mental defects including hydrocephalus, hippocampal dysgenesis, inflammatory and
neuronal defects,16 but none of these defects resembles the phenotype of p57Kip2 null mice
as it should be the case if the two genes are linked to the same regulatory pathway or
belong to a common signaling cascade. Instead, the phenotype of the p57Kip2 null mice is
similar to the knockout phenotypes of p63, the other member of the p53 family:17,18 p63
null mice have severe cranio facial defects, skin and limbs deficiencies and patients affected
by syndromes associated to p63 mutations have cleft palate, limbs deformities and ecto-
dermal dysplasia.19,20 To date, several mutations in the p63 gene have been identified
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associated to several distinct human developmental syndromes,
characterized by common features such as limb abnormalities,
ectodermal dysplasia, and facial clefts.19 These syndromes are: the
Ectrodactyly-Ectodermal dysplasia facial Clefts (EEC), the
Ankyloblepharon-Ectodermal dysplasia-Clefting (AEC), the
Limb-Mammary Syndrome (LMS), the Acro-Dermato-Ungual-
Lacrimal-Tooth (ADULT), and non syndromic Split-Hand/
split-Foot Malformation-4 (SHFM-4). The distribution of mutations
over the various p63 protein domains, and the structural and func-
tional implications of these mutations establish a clear genotype-
phenotype correlation.20
The similarities between the p57Kip2 and p63 null mice suggested
us the possibility that the two genes might be linked to the same
regulatory pathway or belong to a common signaling cascade with
p63 possibly regulating p57Kip2 expression. Here we report that the
∆Np63α isoform is bound to the p57kip2 promoter in vivo and that
a 2 Kb p57Kip2 promoter fragment is activated by the ∆Np63s and
repressed by the TAp63s isoforms in different cell lines. Moreover,
natural p63 mutations, in particular the AEC mutation (Fig. 1),
were indeed altered in their capacity to regulate p57Kip2 transcription
reinforcing the hypothesys that these two genes might be linked to a
common regulatory pathway.
MATERIALS AND METHODS
Cell culture and transfection. The human osteosarcoma Saos-2 cell line
was manteined in RPMI 1640 medium and 10% fetal calf serum. The
murine mesenchymal stem cell line C3H10T(1/2), and the human
osteosarcoma U2OS cell line were manteined in Dulbecco’s modified Eagle’s
medium (D-MEM) and 10% fetal calf serum. For transfection, 80000 cells
were seeded into 24-well multiplates and on the next day transfected with
Lipofectamine 2000 (Invitrogen) under the condition suggested by the
manifacturer. The total amount of transfected DNA (1 µg) was kept costant
using empty vector when necessary. Thirthy six hours later, cells were lysed
and assayed for luciferase activity. The human keratinocyte HaCat cell line
was manteined in D-MEM medium supplemented with 10% fetal calf
serum. HaCat cells were transfected with Fugene (Roche) under the condition
suggested by the manifacturer.
Plasmids. The p63 plasmids were kindly provided by Dr. H. Van
Bokhoven.19 The -2191Kip2, -1550Kip2 and -595Kip2 promoter constructs
were kindly provided by Dr. O. Dellatre.21 The -1091Kip2 promoter construct
was kindly provided by Dr. K. Vousden.15 The -2091Kip2, -1891Kip2,
-1791Kip2 and -1664Kip2 constructs were generated by PCR: different
oligonucleotide pairs were synthetized in order to obtain progressive dele-
tion of the p57Kip2 promoter. The sequences of the oligonucleotides were
as follows:
-2091Kip2 forward:
TTCGGAGCTCGGTAAAGTGGAAAAATAAAAGTA,
-1891Kip2 forward:
TTCGGAGCTCTGGAGTGTGGGTATCCGGG,
-1791Kip2 forward:
TTCGGAGCTCACTTTGCCTCTTTCTGCCC,
-1664Kip2 forward:
TTCGGAGCTCGCGGGAAATTTGTAAATTGTGC.
The revers primer for all reactions was
HpaI: GAGACAGGGCGTTAACCCA.
All oligonucleotides contain adequate restriction sites (underlined) to
allow further cloning steps: the amplification products were purified and
cloned in the pCR 2,1-TOPO vector under the conditions suggested by the
manifacturer (Promega). The cloned fragments were digested with SacI and
HpaI, purified and ligated in the –2191Kip2 vector, partially digested with
SacI and HpaI.
Immunoblot analysis. Thirthy-six hours after transfection cells were
lysed in 60 µl of loading buffer (2% sodium dodecyl sulfate, 30% glycerol,
300 µM β-mercaptoethanol, 100 mM Tris-HCl ph 6.8): 15 µλ of total
extracts were separeted on a SDS-10% polyacrylammide gels and transferred
to a nitrocellulose membrane (Scleicher and Schuell). The blots were incu-
bated with the p57Kip2 C-20 antibody (Santa Cruz Biotecnology) and devel-
oped according to the manufacturee’s instructions (Super Signal, Pierce).
Chromatin immunoprecipitations. Exponentially growing HaCat cells
were washed in PBS, incubated for ten minutes with 1% formaldehyde and
quenched with Glycine 0.1 M. Cells were sonicated and chromatin frag-
ments of an average length of 1 Kb recovered by centrifugation.
Immunoprecipitations were performed with ProtG-Sepharose (KPL, USA),
blocked twice at 4˚C with 1 µg/ml salmon sperm DNA sheared at 500 bp
length and 1 µg/ml BSA, for two hours and overnight. Chromatin was
precleared by adding ProtG-Sepharose for two hours at 4˚C, aliquoted and
incubated with 3–5 µg of the NF-YB purified rabbit polyclonal and p63
antibodies overnight at 4˚C. DNA was released by incubating samples for
five hours at 65˚C, phenol-extracted and ethanol precipitated. Semi quanti-
tative PCRs were performed with the following primers:
-2500 forward: AGGGTATGTAACGCCCCACTGT
-2500 reverse: TGTCAGGAACGCTGTACACCAC
-1600 forward: TGATGGCAGCTACACCCTCTGA
-1600 reverse: CTTGGCTCTTGATGGTGGAACC
core prom for: CCCGCCTGCAGACAAAGGAG
core prom rev: CGGCCGCGATTAGCATAATGTAG
+1000 forward: CTCCTCCCGTGGCATTAAAGG
+1000 reverse: CGCAATGTGCTGTGTAAGCATT
+5000 forward: TGGTGCATACAAAGGTGGTTGG
+5000 reverse: CTAGGGAGGAGGGAGGGATGAA
To produce the anti-p63 antibodies, we cloned TAp63α (Aminoacids
47-611) and SAM-p63, containing the SAM domain (Aminoacids
508-611) into the PET32β prokaryotic expression vector (Novagen, USA).
Recombinant TA-p63 was used to immunize two rabbits. The sera were
affinity-purified over two different columns derivatized with the TAp63 and
SAM-p63 proteins, respectively. We obtained purified antibodies against (1)
the whole protein and (2) specific against to the alpha isoforms. The anti-
bodies were checked in Western blots on all p63 isoforms overexpressed in
eukaryotic cells. The SAM-p63 abs were indeed >10 enriched for anti-TA
and ∆Np63α antibodies (not shown).
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Figure 1 Schematic representation of p63 structure. Intron-exon structure of
the p53 and p63 genes, showing the p63 transcriptional start sites and the
alternative splicing at the 3' end that gives rise to the α, β and γ isoforms.
The changes in the reading frame within exons 14 and 15 occuring in the
β and γ isoforms are indicated. The positions of the four natural p63 mutations
associated to the EEC, AEC, LMS and SHFM-4 syndromes are indicated. All
these mutations affect only the α isoforms.
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RNA analysis. For RNA analysis, 800,000 Saos-2 and U2OS cells were
seeded in 100 mm plates. The next day 5 µg of p63 plasmids were transfected
with Lipofectamine 2000 (Invitrogen) according to the manifacturer condi-
tions. Total RNA was prepared with TRIzol reagent (Sigma). For reverse
transcription (RT)-PCR detection of gene expression, 3 µg of total RNA
was reverse-transcribed using Super Script II (Invitrogen). Total RNA was
extracted from growing HaCaT cells with the RNAeasy kit (Qiagen). Three
micrograms were reverse transcribed using the Super Script II (Invitrogen).
The following oligonucleotides were used for gene amplification:
The oligonucleotidess for the p57Kip2 PCR were described,22
forward: TCGCTGCCCGCGTTTGCGCA
reverse: CCGAGTCGGTGTCCACTTCGG
GAPDH
forward: GTCTCCATCTTCATATGGTAA
reverse: CCACCTTCTTGATGTCATCAT
p63
α isoforms:
forward: GTCTCCATCTTCATATGGTAAC
reverse: CACACTGACTGTAGAGGCA
β isoforms:
forward: AAACGTACAGGCAGCAGCA
reverse: CTTGCCAAATCCTGACAATGCTGC
γ isoforms:
forward: GAGGATAGCATCAGAAAACAGCAAG
reverse: CTCCACAAGCTCATTCCTGAAGC.
RESULTS
∆ Np63α interacts in vivo with three different regions of the
p57Kip2 gene. A prerequisite for activity of a transcription factor
on a putative target gene is the finding that it is bound to relevant
sequences in vivo. The chromatin immunoprecipitation tech-
nique (ChIP) is capable to determine whether this is the case for
p63 in the p57Kip2 gene locus. We used the human keratinocytes
HaCaT cell line for chromatin preparation and three different
anti-p63 antibodies. As controls, we used anti-YB and anti-p53
antibodies. Note that HaCat cells express almost exclusively the
∆Np63α isoform, as well as two p53 alleles mutated in the
DNA-binding domain.23 We scanned the p57Kip2 locus with
different primers. As shown in Figure 2A, of the six amplicons
used, three are strongly positive for p63: -1600, the core promoter
at -200 and +1000. The two latters are also positive for NF-Y, a
result well expected given the presence of consensus CCAAT
boxes in the area. None of the amplicons was positive for p53,
confirming the specificity of our ChIP procedure. The -2500 and
+5000 regions were negative for all antibodies. The -900 amplicon
did show enrichment in both NF-Y and p63 IPs, probably
because of the length of our chromatin (1 Kb) that allowed some
lateral amplification. However, this was far less pronounced than
for the -1600 and core promoter amplicons.
In order to verify whether the association of ∆Np63α with the
p57Kip2 gene was functional in these cells, total RNA was extracted
from HaCat cells and used in RT-PCR reactions with oligonu-
cleotides specific for the p57Kip2 transcript: as shown in Figure 2B
the p57Kip2 mRNA is indeed expressed in HaCat cells.
Therefore, in growing HaCat cells, p63 is functionally associ-
ated in vivo to the p57Kip2 gene at three different positions.
A -2191 bp fragment of the p57Kip2 promoter is regulated by
p63 isoforms. The ChIP experiments prompted us to tackle a
functional analysis of the p57Kip2 promoter, taking into accounts
two facts: (1) a fragment of 1 kb of the p57kip2 promoter was
shown to be not responsive to p73 and p53 cotransfection:15 (2)
p63 binds to -1.6 Kb from the start site. We therefore employed
a larger fragment of the p57Kip2 promoter, up to -2191 bp, in
transient transfection experiment in the HaCat cell line where p57Kip2 is
expressed endogenously: as shown in Figure 2C, transfection of serial doses
of the TAp63α and TAp73β marginally affected the expression of the
p57kip2 promoter fragment while transfection of TAp73α and to a greater
extent ∆Np63α induced its expression. We next performed cotransfection
experiments of the -2191 p57Kip2 promoter with all p63 isoforms, p53,
TAp73α and TAp73β in the U2OS human osteosarcoma cell line, express-
ing p53 but not p63, to verify whether members of the p53 family could
regulate its expression. As shown in Figure 3A, in the U2OS cells the -2191
p57Kip2 promoter activity was marginally affected by cotransfection of serial
doses of TAp63α, TAp63β, TAp63γ, p53 and TAp73β expression plasmids;
on the other hand, cotransfection of TAp73α led to an increase of the basal
activity of the -2191 promoter construct and all ∆Np63 isoforms similarly
transactivate this promoter, with the ∆Nα isoform being the strongest
transactivator (10 fold). We repeated the same experiments in the Saos-2 cell
line, that express no p53 and no p63, and very similar results were obtained
(data not shown).
In the murine mesenchymal cell line C3H10T(1/2), in which p57Kip2
expression has been studied,24 a completely different scenario was obtained:
cotransfection of the ∆Np63 isoforms and TAp73α did not have any effect
on the -2191p57Kip2 promoter activity, while p53, TAp73β and all TAp63
isoforms had a strong repressive effect on this promoter fragment (Fig. 3B).
These data indicate that the ∆Np63 isoforms and p73α activated the
-2191 p57Kip2 promoter in the U2OS cell line, while the TAp63 isoforms
had a strong repressive effect on the -2191 promoter in the C3H10T(1/2)
cells and this activity was shared by p53 and TAp73β.
The -1600 region of the p57Kip2 promoter is necessary for p63 action.
In order to identify the region of the p57Kip2 promoter responsible for the
Figure 2. ChIP analysis of the p57Kip2 promoter. (A) HaCat chromatin was immuno-
precipitated with the indicated antibodies (antiYB, anti-p63 from Santa Cruz and two
anti-p63 rabbit antibodies against the whole p63 and against the SAM domain).
Several amplicons were used in semi-quantitative PCR amplifications. The -1600 and
+1000 regions are highly positives with the three anti-p63 antibodies; the core
promoter with the SC-H137. Black boxes: NF-Y binding sites. (B) RT-PCR analysis of
endogenous p57Kip2 expression in HaCat cells: (lane 1, molecular weight marker: lane
2, p57Kip2: lane 3 negative control, no DNA). (C) Transcriptional activation of a
-2191bp p57Kip2 reporter plasmid by p63 and p73. HaCat cells were transfected with
the -2191bp p57Kip2 reporter plasmid (0.2 µg) (black bar). Different quantities of
expression plasmids for p63 and p73 isoforms were cotransfected (0.1, 0.3, 0.5 µg
white, light grey and dark grey bars respectively). Cells were lysed after 36 hours and
luciferase activity was determined. The basal activity of the reporter plasmids was set
to 1. Data are presented as fold activation/repression relative to the sample without
effector. Each histogram bar represents the mean of three indipendent transfection
duplicates. Standard deviation are indicated.
A B
C
observed regulation by ∆Np63 and TAp63 isoforms, we employed deletion
constructs of the p57Kip2 promoter15,21 in cotransfection experiments with
the ∆Np63α isoform in the U2OS cell line and with the TAp63α isoform
in the C3H10T(1/2) cell line. The results clearly showed that deletion of a
region encompassing -2191 and -1550 bp of the p57kip2 promoter resulted
in substantial loss of both activation and repression by the ∆Np63α and
TAp63α isoforms respectively (Fig. 4A and 4B, compare the –2191 and the
-1550 constructs): the -1550 bp construct retained however a residual two
fold activation and repression in response to ∆Np63α and TAp63α cotrans-
fection, suggesting that two regions of the p57Kip2 promoter are sensitive to
p63 overexpression and this is well in line with the ChIP data that showed
p63 binding to the -1600 region and to the proximal promoter region (Fig. 2A).
To further narrow the p63 responsive region we generated nested deletion
of the -2191/-1550 region by PCR, generating the -1880 (not shown), -1778
and -1664 constructs. Cotransfection of these constructs in the U2Os cell
line with ∆Np63α showed that indeed deletion of the region around –1600
(compare the -1664 and -1500 constructs, (Fig. 4A) resulted in a significant
loss of activation by ∆Np63α cotransfection. This region was necessary also
for repression by the TA isoforms in the the C3H10T(1/2) cell line (Fig. 4B).
These results indicate that the same region of the p57Kip2 promoter
around -1600 is responsible for the activation seen in the U2OS cell line by
∆Np63s and for the repression seen with TAp63s in the C3H/10T(1/2) cell
line. Moreover, two regions of the p57Kip2 promoter are responsive to p63:
the -1600 region and the core promoter region.
The AEC natural p63 mutations subvert p57Kip2 regulation. The
initial observation of the partial overlap between the p57Kip2 null mice, the
p63 null mice phenotypes and the patients affected by syndromes associated
to p63 mutations, prompted us to analyze the activities of natural p63
mutants associated with four different human syndromes on the -2191
p57Kip2 promoter fragment. Cotransfections experiments of natural p63
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Figure 3. The p57Kip2 promoter is regulated by p63 isoforms. (A)
Transcriptional activation of a -2191bp p57Kip2 reporter plasmid by p63,
p73 and p53. U2OS cells were transfected with the -2191bp p57Kip2
reporter plasmid (0.2 µg) (black bar). Different quantities of expression
plasmids for p63 isoforms, p73 and p53 were cotransfected (0.1, 0.3, 0.5
µg white, light grey and dark grey bars respectively). Cells were lysed after
36 hours and luciferase activity was determined. The basal activity of the
reporter plasmids was set to 1. Data are presented as fold activation/repres-
sion relative to the sample without effector. Each histogram bar represents
the mean of three indipendent transfection duplicates. Standard deviation
are indicated. (B) Transcriptional repression of a -2191bp p57Kip2 reporter
plasmid by p63, p73 and p53. C3H10T1/2 cells were transfected with the
-2191bp p57Kip2 reporter plasmid (0.2 µg) (black bar). Different quantities
of expression plasmids for p63 isoforms, p73 and p53 were cotransfected
(0.1, 0.3, 0.5 µg) (white, light grey and dark grey bars respectly). Cells
were lysed after 36 h and luciferase activity was determined. The basal
activity of the reporter plasmids was set to 1. Data are presented as fold
activation/repression relative to the sample without effector. Each histogram
bar represents the mean of three indipendent transfection duplicates.
Standard deviation are indicated.
Figure 4. A 100 base pairs region is required for p57Kip2 regulation by
p63. (A) Progressive deletions of the -2191 p57Kip2 promoter were cotrans-
fected in U2Os cells with different quantities of expression plasmids for
∆Np63α (0.1, 0.3, 0.5 µg) (white, light grey and dark grey bars respectly).
The basal activity of the reporter plasmids (0.2 µg) was set to 1 (black bar).
Cells were lysed after 36 hours and luciferase activity was determined. Data
are presented as fold activation/repression relative to the sample without
effector. Each histogram bar represents the mean of three indipendent
transfection duplicates. Standard deviation are indicated. Each histogram
represents the fold of activation or repression relative to the sample.
Standard deviation are indicated. (B) The same constructs as in (A) were
cotransfected with TAp63α in C3H10T(1/2) cells.
A
B
A
B
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mutants in the U2OS cell line clearly showed that the ∆N-AEC518 mutant
completely lost any transactivation potential while the ∆N-∆AA mutant had
an increased activation potential: the ∆N-EEC and the ∆N-SHFM behaved
as the wild type α isoform (Fig. 5A). The TA mutant isoforms behaved as
the wild type TA isoform, having no effect on the basal level of the p57Kip2
promoter, with the exception of the TA-AEC518 that had a strong activation
capacity. In the C3H10T(1/2) cotransfection of the ∆N mutant isoforms
did not have effect on the activity of the -2191 promoter construct, behaving
like wild type ∆Np63α. On the other hand, of the TA isoforms only the
TA-AEC518 isoform was ineffective in repressing the basal activity of the
-2191 construct while the other three mutants retained this ability. These
data demonstrate that p57Kip2 regulation is profoundly altered in the AEC
p63 mutant.
The endogenous p57Kip2 gene is activated by ∆Np63 overexpression.
Our data indicated that members of the p63 family regulate the expression
of a p57Kip2 promoter fragment when overexpressed and that some of the
p63 mutants analysed were impaired in this activity. In order to verify
whether the endogenous p57Kip2 gene was subject to the same regulation as
the promoter construct used, we transiently transfected the U2Os and
Saos-2 cell lines with wild type and mutated ∆Np63 isoforms. The day after
trasfection, total RNA was extracted and used in RT-PCR reactions with
oligonucleotides specific for the p57Kip2 transcript. As shown in Figure 6A
and 6B, the p57Kip2 was activated in response to ∆Np63α, ∆Np63β and
∆Np63∆γ overexpression (lanes 2, 3 and 4). The ∆N-EEC, ∆N-SHFM and
∆N-∆AAp63 mutants were still able to activate p57Kip2 gene expression
(lanes 6, 7 and 8) while the ∆N-AEC518 mutant completely failed to do so
(lanes 5). In accordance with these data, the endogenous p57Kip2 protein
levels were increased upon ∆Np63α transfection (Fig. 6C). These data
indicate that the ∆Np63 isoforms transactivate endogenous p57Kip2 gene
expression and this activity is lost in the AEC natural p63 mutant.
DISCUSSION
Precise control of cell cycle progression is believed to be critical
for normal development, while oncogenesis may be a direct result of
its disturbance. Cell cycle progression is regulated predominantly by
a series of serine/threonine kinases, the cyclin-dependent kinases
(CDKs). The activities of the CDKs are controlled by a group of
molecules that inhibit CDK activity, the CDK inhibitors (CKIs). It
is widely believed that precise regulation of CKI expression is critical
for appropriate development and that breakdown of this regulatory
mechanism is deeply involved in oncogenesis and abnormal develop-
ment. Evidence for this has been provided by the observation that
some CKI knockout mice show developmental abnormalities and a
predisposition to cancer development.
To date, seven CKIs have been identified in mammals and cate-
gorized into two families, the Cip/Kip and Ink4 families. The
Cip/Kip family is composed of p21Cip1, p27Kip1 and p57Kip2 and is
well conserved phylogenetically but, despite the structural and
biochemical similarities among the Cip/Kip members, the pheno-
types of knockout mice of each Cip/Kip member are surprisingly
different and the p57Kip2 is the only CDK inhibitor to be required
for a correct embryogenesis. The p57Kip2 protein ceases to be
expressed in most organs as an embryo completes its development,
in contrast to p27Kip1, the expression of which remains constant
after birth, implying that p57Kip2 plays an important role predomi-
nantly in early organogenesis. Most p57-deficient mice die immedi-
ately after birth due to dyspnea resulting from severe cleft palate,
abdominal muscle defects and skeletal abnormalities due to bone
ossification defects.12,14 About 10% of the p57-deficient mice survived
beyond the weaning period without showing cancer predisposition.
Little is known about p57Kip2 transcriptional regulation while
that of p21Cip1 has been investigated extensively25,26 and turned out
to be quite complex; similarly, the regulation of p27Kip1 seems equally
articulated.27
Here we report that the cyclin-dependent kinase inhibitor
p57Kip2 gene is a target for p63 mediated transcriptional activation
and repression and that three regions of the p57Kip2 gene are bound
by p63 in vivo. The ChIP analysis performed with three anti-p63
antibodies determined that the p57Kip2 gene is bound by the p63
protein in vivo. Interestingly, the scanning analysis suggests that
there are three major areas of binding: an upstream region, which is
the focus of the functional analysis perfomed, the core promoter and
a downstream region, whose functional importance was not investi-
gated in the present study. Neither the upstream, nor the core
promoter contain bona fide p53 binding sites, suggesting that p63
recognizes DNA through different motifs, or that other DNA-binding
factors mediate the association.28
The upstream binding site has been funtionally dissected.
Members of the p53 family, p53 and p73β, failed to induce the
-2191 bp p57kip2 promoter fragment, while p73α and all ∆Np63
isoforms induced its expression both in HaCat and U2Os cells; all
TAp63 isoforms did not alter promoter activities in these cells. On
the other hand, the TAp63 isoforms, p53 and p73β had a strong
repressor activity in C3H10T(1/2) cells where all ∆Np63 and p73α
were totally inert. The different behaviour of p63, p53 and p73 in
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Figure 5. The AEC mutation subvert p63 transcriptional potential. (A)
Transcriptional regulation of a -2191bp p57Kip2 reporter plasmid by AEC,
EEC, LMS and SHFM mutations. U2OS cells were transfected with the
-2191bp p57Kip2 reporter plasmid (0.2 µg) (black bar). Different quantity of
expression plasmids for p63 mutants were cotransfected (0.1, 0.3, 0.5 µg)
(white, light grey and dark grey bars respectly). Cells were lysed after 36 h
and luciferase activity was determined. The basal activity of the reporter
plasmids was set to 1. Data are presented as fold activation/repression
relative to the sample without effector. Each histogram bar represents the
mean of three indipendent transfection duplicates. Standard deviation are
indicated. (B) The same constructs as in (A) were cotransfected with TAp63α
in C3H10T(1/2) cells.
A
B
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the four cell lines used can be due to differential expression of still
unknown cofactors that can stimulate/repress p53 family members
activities. The differential ability of various p63 isoforms to induce
target genes expression has been described in previous studies.29,30
Our attempts to delineate a p63-responsive element in the -2191
promoter region of p57Kip2 have led to the identififcation of a 100 bp
fragment that, when deleted, cause a drastic reduction of p63 acti-
vation in U2Os cells and a concomitant reduction of repression in
C3H10T(1/2) cells, suggesting that both activation and repression
are mediated by the same 100 bp region. We further dissected this
fragment in EMSA experiments with nuclear extracts derived from
cells expressing exogenous and endogenous p63 (not shown); all our
attempts to evidenziate p63 binding to this region failed. It is well
possibile that the conditions employed for binding are not optimal
for p63 binding but we rather think that that other DNA-binding
factors mediate the association.28
A second p63 site was detected in the core promoter region.
Here, again, no p53 element is found. We note that there are multiple
CCAAT boxes in the promoter; CCAAT boxes are recognized and
activated by the NF-Y trimer. NF-Y was recently shown to be required
for the association of p53 to promoters of G2/M controlling genes
in mouse NIH3T3, in the absence of p53-binding sites.31 Indeed,
p57kip2 ChIPs positivity for NF-Y is limited to the core promoter
and the +1000 region: the presence of multiple CCAAT in the core
promoter suggests that indirect binding of p63 through CCAAT-
bound NF-Ys is the likeliest possibility to explain p63 positivity in
the core promoter. Association of ∆Np63α with multiple CCAAT
promoters through direct protein-protein recruitment has been
observed (Testoni B, Mantovani R, submitted).
The ∆Np63α is known to behave as a domint negative factor for
p53 transcriptional activity. HaCat keratinocyets contain two
mutant p53 alleles:23 consistent with this, none of these binding
sites are recognized by p53 in our study. We and others have shown
that this isoform, which is devoid of the N-terminal activation
domain, is nevertheless capable to activate p53 targets.29,32 One
important finding from our study is that indeed ∆Np63α is the
most potent of activators among the different isoforms on the p57Kip2
promoter. Together with the ChIP data, this strongly suggests that
p57Kip2 is a physiological target in vivo of this isoform. The TA
domain is evidently dispensable for this, and p53 is manifestly not
involved. It was important to control this, since p53 mutated in the
DNA-binding domain are known to possess a higher affinity for p63
and p73. HaCat keratinocyets contain two mutant p53 alleles:23
consistent with this, none of these binding sites are recognized by
p53 in our study.33 Thus it is not through heterotetramerization that
the p63 presumed tetramer works, equally indicating that activation
is not brought by the p53 TA domain. Hence, the additional activation
domain identified at the C-terminal of the ∆Np63α is manifestly
providing the activation potential.29 In general, these data strengthen
the notion that bona fide targets of this isoform exist that are solely
activated, and not repressed.
The AEC p63 mutation profoundly affected p63 trascriptional
activity, turning the ∆N isoform in a weak activator of the p57Kip2
promoter and the TA isoform in an activator instead of a repressor.
This scenario suggests that during development the expression of the
p57kip2 gene would be differentially regulated by the same pattern of
genes in different cell types. The observation of a clear alteration of
p57Kip2 expression by ∆Np63AEC mutants, together with the fact
that p57kip2 null mice mice share similar features with AEC patients
(cleft lips and palates) suggests that p57Kip2 may act in the develop-
mental pathways altered in AEC ectodermal displasia. We have
evidences that only the ∆Np63 isoforms are expressed during mouse
development from E10 through E14 in the limb buds and in the
branchial arches (manuscript in preparation) and mounting evidence
suggests that the ∆Np63α isoform is predominant in stem cells of
multilayered epithelia, in particular keratinocytes.34,35 Because AEC
patients also have dermatological abnormalities,36 abnormal regulation
of p57kip2 as suggested by our experiments might contribute to the
emergence of the skin phenotype as well.
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